Drug Trial Radar · NCT06073132
An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)
Last checked: Nov 20, 2026Latest source record: Jul 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Apr 4, 2024
Primary completion
Jun 10, 2026
Study completion Mar 2027
Sponsor
- Lead sponsor
- TWi Biotechnology, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 10, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The proposed Phase 2/3 trial with double-blind and open-label extension phases is an international, multicenter study designed to assess the efficacy and safety of diacerein 1% ointment in patients with generalized EBS.
Conditions
- Generalized Epidermolysis Bullosa Simplex
Interventions
AC-203Drug
The investigational product is formulated as 1% topical ointment
VehicleDrug
Vehicle-only control study medication is the same formulation as investigational product without active ingredient
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of patients achieving treatment success on the IGA of the Treatment Area, in which treatment success is defined as a score of 0 or 1 with at least a 2-point reductionTime frame: from Baseline A (Visit 2/Day 1) to Week 8 (Visit 5/EOT)
Locations
30 sites in 18 countries. Site status is shown where the registry gives one.
Mission dermatology Center
Rancho Santa Margarita, California
Stanford University
Stanford, California
Children's Hospital Colorado
Aurora, Colorado
Northwestern University - Lurie Childrens's Hospital
Chicago, Illinois
Cincinnati Childrens Hospital
Cincinnati, Ohio
Medical University of South Carolina
Charleston, South Carolina
Texas Dermatology and Laser Specialists
San Antonio, Texas
Premier Specialists
Kogarah, Australia
Sydney Children's Hospital
Randwick, Australia
Universitaetsklinik fuer Dermatologie und Allergologie
Salzburg, Austria
UZ Leuven
Leuven, Belgium
Dermatology Hospital of Southern Medical University
Guangzhou, Guangdong, China
Hospital of Skin and Venereal Diseases of Thessaloniki
Thessaloniki, Greece
Postgraduate Institute of Medical Education and Research (PGIMER)
Chandigarh, India
Children's Health Ireland
Dublin, Ireland
Tel Aviv Sourasky Medical Center
Tel Aviv, Israel
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milano
Milan, Italy
Università degli Studi di Modena e Reggio Emilia (UNIMORE)
Modena, Italy
Istituto Dermopatico dell'Immacolata (IDI) - Istituto di
Rome, Italy
UOS "Centro delle Dermatosi Croniche Complesse e Genodermatosi" UOC Dermatologia
Rome, Italy
Hospital Tunku Azizah (Hospital Wanita Dan Kanak-kanak Kuala Lumpur)
Kuala Lumpur, Malaysia
Asian Hospital
City of Muntinlupa, Philippines
Iloilo Doctors Hospital
Iloilo City, Philippines
Health Cube Medical Clinics
Mandaluyong, Philippines
OT.CO Clinic Osipowicz & Turkowski
Warsaw, Poland
Gangnam Severane Hospital
Seoul, South Korea
Hospital Universitario La Paz
Madrid, Spain
National Cheng Kung University Hospital
Tainan, Taiwan
Sheikh Khalifa Medical City (SKMC)
Abu Dhabi, United Arab Emirates
Great Ormond Street Hospital (GOSH) for Children NHS Foundation Trust - Somers Clinical Research Facility (CRF)
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.